VRPX - Virpax Pharmaceuticals, Inc.

0.6695
-0.551   -82.226%

Share volume: 2,782,368
Last Updated: 04-03-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$1.22
-0.55
-0.45%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 43%
Liquidity 28%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
252.55%
2 Year
-85.22%
Key data
Stock price
$0.67
P/E Ratio 
0.00
DAY RANGE
$0.45 - $1.18
EPS 
-$5.30
52 WEEK RANGE
$0.10 - $3.77
52 WEEK CHANGE
$252.55
MARKET CAP 
1.616 M
YIELD 
N/A
SHARES OUTSTANDING 
4.888 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-21-2025
NEXT EARNINGS DATE
04-29-2025
BETA 
-0.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Anthony P. Mack
Region: US
Website: virpaxpharma.com
Employees: 7
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Virpax Pharmaceuticals, Inc. develops various drug-delivery systems and drug-releasing technologies. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee. AnQlar, an anti-viral barrier to prevent or reduce the risk of viral infections in humans, including influenza and SARS-CoV-2.

Recent news